 |
Dr Warwick Nesbitt and colleague Dr Crispin Szydzik. Image: Medtech |
Congratulations to Dr Warwick Nesbitt, Australian Centre for Blood Diseases (ACBD) and Dr Gregory Stewart who are set to transform their research impact.
The MedTech Actuator Menzies Fellowship is supported by the Menzies Foundation as part of their Entrepreneurship in Science mission in partnership with the MedTech Actuator.
The Fellowship will provide Warwick and Gregory with a strong grounding in entrepreneurship, commercialisation, and the startup ecosystem. This will help to unlock the potential of their respective research on cardiovascular disease and schizophrenia.
Dr Nesbitt said, "The Menzies Fellowship will allow me to access the expertise and network of the MedTech Actuator to accelerate the commercialisation of a novel blood platelet bioreactor under development within the ACBD.
"The MedTech Actuator will give me the opportunity to access an extensive ecosystem of MedTech partners spanning product development firms, multinational MedTech corporations, and investors."
He said that the fellowship will support ongoing research within the Haematology Micro-platforms Group, ACBD, focussed on the development of a novel platform of blood handling lab-on-a-chip devices with applications to blood platelet testing and new anti-thrombotic drug discovery.
Read the story: medtechactuator.com/medtech-actuator-menzies-fellows-2022-announced/
See more about Dr Nesbitt's research: www.monash.edu/medicine/ccs/blood-disease/research/haematology-micro-platforms
No comments:
Post a Comment
Thankyou for your comment. We moderate all messages and may take a little time to review your comment. Please email inquiries to ccs.comms@monash.edu.